Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 2,652 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Completed Phase 4 Interventional

Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip

NCT00868088
View directory record Official record
Conditions
Actinic Cheilitis, Squamous Cell Carcinoma In-situ (SCC-is), Squamous Cell Carcinoma (SCC), Photodynamic Therapy (PDT), Mohs Surgery
Interventions
PDT prior to Mohs surgery
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Response of Topical Capsaicin in Alopecia Areata

NCT00176969
View directory record Official record
Conditions
Alopecia Areata
Interventions
Capsaicin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 28, 2026, 5:27 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Optimizing Pain Control in Transurethral Resection of the Prostate

NCT04102566
View directory record Official record
Conditions
Pain, BPH With Urinary Obstruction, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions
Ibuprofen 600 mg, Education
Drug · Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Results available

Evaluating Treatment Resistant Dermatitis TaroIIR

NCT03050294
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Phone calls, Desoximetasone 0.25% spray
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Results available

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

NCT02340169
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Topicort® (desoximetasone) Topical Spray, 0.25%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 28, 2026, 5:27 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Observing Performance of Haptic Vibrotactile Trigger Technology by Measuring Changes in Resting Metabolic Rate: Assessment and Analysis

NCT07781384
View directory record Official record
Conditions
Resting Metabolic Rate, Energy Metabolism, Haptic Technology, Vibrotactile Stimulation
Interventions
IGNITE Patch (Active), Inactive patch
Device
Lead sponsor
SuperPatch Limited LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tyrone, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 4 Interventional

A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens

NCT01061268
View directory record Official record
Conditions
Dry Eye
Interventions
No topical artificial tear, Blink® Tears Lubricant Eye Drops
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Bexarotene, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 28, 2026, 5:27 PM EDT
Terminated Phase 2 Interventional

Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

NCT07168148
View directory record Official record
Conditions
Nasal Obstruction, Chronic Rhinitis
Interventions
Oxymetazoline + Triamcinolone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07284381
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ABBV-444, REFRESH OPTIVE UD
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Dothan, Alabama • Chandler, Arizona • Azusa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 2 Interventional

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

NCT00432185
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Mesa, Arizona • Oceanside, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

NCT00684177
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retapamulin Ointment, 1%, Placebo ointment
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Months and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
32
States / cities
Tucson, Arizona • Anaheim, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Not applicable Interventional

A Randomized Control Trial for Preventative Scar Management

NCT01602458
View directory record Official record
Conditions
Hypertrophic Scarring
Interventions
Silicone Only Therapy (SOT), Silicone Pressure Garment Therapy (SPGT)
Procedure
Lead sponsor
Seton Healthcare Family
Other
Eligibility
1 Year to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 28, 2026, 5:27 PM EDT
Completed No phase listed Observational

Topical Antisepsis in Head and Neck Cancer Surgery

NCT04721626
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Chlorhexidine Gluconate, Povidone-iodine, Tetracycline Ointment
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 4 Interventional

Enstilar in Combination With Biologic Agents

NCT03080545
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00674739
View directory record Official record
Conditions
Genital Warts
Interventions
Imiquimod, 3.75% imiquimod cream, placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 28, 2026, 5:27 PM EDT
Active, not recruiting Phase 2 Interventional

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

NCT07065773
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
Trichostatin A
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Fremont, California • Denver, Colorado • New Brighton, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Recruiting Early Phase 1 Interventional

Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

NCT07298057
View directory record Official record
Conditions
Periodontitis, Diabetes Mellitus Type 2
Interventions
local antibiotic application of topical minocycline, Scaling and Root Planing
Drug · Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01072357
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

NCT00470379
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
resiquimod
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 28, 2026, 5:27 PM EDT
Suspended Phase 4 Interventional

Pharmacokinetic Study of Synera™ in Neonates and Infants

NCT00747669
View directory record Official record
Conditions
Pain
Interventions
lidocaine 70mg and tetracaine 70mg topical patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
Up to 4 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 28, 2026, 5:27 PM EDT
Completed No phase listed Observational

Minoxidil Response Testing in Males With Androgenetic Alopecia

NCT02198261
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% minoxidil topical foam
Drug
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tucson, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks

NCT02601105
View directory record Official record
Conditions
Stretch Marks, Striae Distensae, Cosmetic Appearance of Stretch Marks
Interventions
Placebo Vehicle Cream, Centella Asiatica Cream
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 28, 2026, 5:27 PM EDT